The Rohatyn Group Agrees to Sell Leading Omni Channel Pet Care Platform Pet Network International to A&M Capital Europe
The Rohatyn Group (“TRG”), a global, US-based asset management firm with expertise in emerging markets and real assets, and A&M Capital Europe (“AMCE”), a London-based, operationally-focused European middle-market private equity firm, today announced that they have entered into a definitive agreement under which TRG will sell Pet Network International d.o.o. (“Pet Network” or “the Company”) to AMCE. Pet Network is the leading omni channel pet care platform in southeast Europe, operating across Croatia, Romania, Slovenia, Serbia and Bulgaria. The transaction, terms of which were not disclosed, is expected to close in the third quarter of 2021.
Pet Network was created by TRG in 2018 through the acquisition and merger of three distinct businesses active in the pet supplies industry across southeast Europe: Pet Centar, which operates in Croatia, Serbia and Romania; Animax, which operates in Romania; and Mr. Pet, which operates in Slovenia. The origins of the group date back to 1999 when the first Pet Centar store was opened in Croatia. Today the Company operates more than 150 physical stores across five countries under the Pet Centar, Maxi Pet, Animax and Mr. Pet brands. The Company also operates various eCommerce channels as well as a growing offering of value-added services including veterinary pharmacies.
TRG Managing Directors Stepan Karpukhin and Harold Chatelus commented: “Pet Network is a fast growing and highly successful business that has benefitted from the global trends around pet humanization, combined with high levels of pet ownership across southeast Europe. The Company’s talented management team, led by CEO Ljiljana Markov Medugorac, has played a vital role in capitalizing on this positive momentum and will continue to run the business post the transaction closing.”
Colin Clark, Head of EMEA at TRG, added: “In line with TRG’s buy-and-build philosophy, during our ownership period, Pet Network has delivered remarkable growth and transformed into a sizeable business on a European scale. We are confident that AMCE is the right partner for Pet Network’s next chapter and are pleased to have found a like-minded investor to further the Company’s growth story.”
Ljiljana Markov Medugorac, CEO of Pet Network International commented: “TRG’s acquisition three years ago was an important milestone that helped us achieve rapid growth, add-on acquisitions, many new store openings, online expansion, an expanded own brands portfolio and countless other initiatives. Navigating through a global pandemic over the past year, we also expanded our operations to a new exciting market, Bulgaria. We are all proud of Pet Network's teams achievements, which were strongly backed up with TRG's support and guidance. While we will be sad to say goodbye to our colleagues at TRG, we are also excited to start the next chapter in the company’s development in partnership with AMCE, who like TRG share our vision for the company’s future growth.”
TRG CEO Nick Rohatyn added, “We are proud of our investment in Pet Network. This represents a landmark transaction for the European team as well as TRG globally. Given the strong growth drivers underpinning the pet space, TRG views this as a highly attractive sector. Our experience with Pet Network represents a great example of the innovative consumer focused businesses that can benefit from consolidation and pan-European scale that we like at TRG.”
TRG was advised on the transaction by William Blair (M&A), Deloitte (Financial & Tax), Baker McKenzie (Legal), Babic (Legal) and BCG (Commercial).
AMCE was advised by Houlihan Lokey and Alantra (M&A), Alvarez & Marsal (operations), Dickson Minto (Legal), EY (Financial & Tax), AT Kearney (Commercial).
About TRG
Founded in 2002, The Rohatyn Group is an asset management firm focused on emerging markets and real assets headquartered in New York, with a presence around the globe including Boston, Buenos Aires, Montevideo, Lima, São Paulo, London, Cairo, Mumbai, New Delhi, Singapore, Hanoi, Kuala Lumpur and Rotorua. For more information, please visit www.rohatyngroup.com
About AMCE
AMCE is a London based, operationally growth focused European middle-market private equity firm. AMCE Fund I currently manages €650 million of committed capital and is part of A&M Capital, the global multi-strategy private equity firm managing in excess of €3 billion of capital. AMCE has an association with Alvarez & Marsal consulting (“A&M”) that enables AMCE to access the world class operational expertise of A&M’s almost 4,500 consultants across A&M’s 23 European offices and 65 offices globally. For more information, please visit www.a-mcapital.com/europe/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210715006085/en/
Contact information
The Rohatyn Group:
Julie Rudnick / Columbia Clancy
Sard Verbinnen & Co
TRG-SVC@SARDVERB.com
AMCE:
Rob Brown / Ben Valdimarsson
ReputationInc
(353) 85-7252626
rbrown@reputation-inc.com / bvaldimarsson@reputation-inc.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Agendia to Present Five Posters Demonstrating the Expanding Clinical Utility of MammaPrint + BluePrint at the 2025 San Antonio Breast Cancer Symposium4.11.2025 14:00:00 EET | Press release
Agendia®, Inc., a leader in precision oncology for breast cancer, today announced it will present new results from the ongoing real-world FLEX Study (NCT03053193) at the 2025 San Antonio Breast Cancer Symposium (SABCS), taking place December 9-12 in San Antonio, Texas. The company will present five posters, led by Agendia investigators and independent academic collaborators, that collectively highlight the broad clinical impact of MammaPrint® + BluePrint® genomic profiling in optimizing treatment decisions and improving outcomes for patients with hormone receptor positive, HER2-negative (HR+/HER2–) early breast cancer (EBC). “We look forward to sharing these new findings from the FLEX Study, which spans more than 20,000 participants across 100 global sites, making it the largest and most diverse real-world evidence cohort for early-stage breast cancer,” said William Audeh, M.D., Chief Medical Officer at Agendia. “These results underscore our commitment to generating robust clinical evi
Nature Communications Study Supports HER2DX as a Genomic Tool for Tailored Therapy in Older Individuals With HER2+ Breast Cancer4.11.2025 14:00:00 EET | Press release
REVEAL GENOMICS, S.L., a Barcelona-based biotechnology company seeking to revolutionize precision oncology through biomarker innovation, today announced the publication of the study “HER2DX in older patients with HER2-positive early breast cancer: extended follow-up from the RESPECT trial of trastuzumab ± chemotherapy” in Nature Communications. This landmark study evaluated the HER2DX genomic assay in 154 individuals aged 70–80 years enrolled in the RESPECT trial (NCT01104935), a randomized phase III study comparing adjuvant trastuzumab with or without chemotherapy. The analysis, known as Trans-RESPECT, is the first to evaluate HER2DX in an older adult population, a demographic historically underrepresented in clinical trials. Bringing Precision Oncology to Older Individuals with HER2+ Disease Despite the growing number of older adults diagnosed with HER2-positive early breast cancer, optimal treatment strategies remain unclear. Many face increased risks of chemotherapy-related toxicit
Compass Pathways Announces Third Quarter 2025 Financial Results and Business Highlights Including Acceleration of Commercial Launch Plans by 9-12 Months4.11.2025 13:30:00 EET | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today reported its financial results for the third quarter 2025 and provided an update on recent progress across its business. “With the completion of COMP006 enrollment and our recent positive discussions with the FDA, we are excited about pulling forward our expected launch timing for COMP360 in TRD by 9-12 months,” said Kabir Nath, Chief Executive Officer at Compass Pathways. “We are accelerating commercial launch plans to match this new expected timeline with the goal of advancing our mission of transforming the mental health landscape and how patients living with depression are treated.” Business Highlights COMP360 psilocybin treatment in TRD (Treatment Resistant Depression) Second Phase 3 trial, COMP006, has completed enrollment (n=585) In June 2025, we announced achievement of the 6-week primary endpoint in the first of two phase 3
TELEO Capital Closes Oversubscribed TELEO Capital II at $350 Million Hard Cap4.11.2025 13:00:00 EET | Press release
TELEO Capital Management, LLC (“TELEO”), an operationally focused private equity firm focused on investing in lower middle market enterprise software companies, today announced the final close of TELEO Capital II (“Fund II”) at its hard cap of $350 million in Limited Partner capital commitments. Fund II was oversubscribed and attracted a diverse group of new and existing institutional investors. TELEO executes a time-tested strategy in the lower middle market, leveraging a large purpose-built team and repeatable process designed to deliver consistent, outsized returns. Fund II will continue TELEO’s focus on acquiring mission-critical software divisions of large corporations. TELEO is an ideal partner to large corporate sellers in need of a solution where speed and certainty to close, minimal post-closing distraction risk from shared services agreements, and a commitment to protecting customer and employee relationships are extremely important. “We are honored by the trust our investors
Celonis Partners with Databricks to Power Enterprise AI that Continuously Improves Business Operations4.11.2025 12:00:00 EET | Press release
Celonis, a global leader in Process Intelligence, today announced a partnership with Databricks, the Data and AI company, to provide customers with a seamless, powerful pathway to operationalize AI. The integration leverages Delta Sharing to directly connect the Celonis Process Intelligence Platform with the Databricks Data Intelligence Platform. Delta Sharing is Databricks’ open source approach that enables customers to share live data across platforms, clouds and regions with strong security and governance. This bi-directional integration, powered by Delta Sharing, eliminates the need to move or copy data between the two platforms. It breaks down data silos, reduces data copies, limits synchronization errors, enhances security, and simplifies data governance. With data and process intelligence flowing freely between the two platforms, customers get a continuous learning loop for AI-driven operations. Customers can use Celonis to read live data stored in Databricks and enrich it with
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom